Key facts
- Elysium Therapeutics’s last known valuation is $28.3M (Oct 2022).
- It has raised $11.5M across 1 recorded rounds; the latest was Seed Round ($2.2M) in Nov 2020.
- Notable investors include New York Angels, SeedFolio, Ohio Department of Development, Innovations for Impact, Mesa Verde Venture Partners — 9 tracked in total.
- Elysium Therapeutics has filed 2 Form Ds with the SEC since 2020, most recently Oct 2022 ($2.2M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Elysium Therapeutics
Funding rounds
1 roundsAbout Elysium Therapeutics
Developer of opioid pain relievers designed to protect individuals from oral misuse, abuse, and fatal overdose. The company's pain medications automatically prevent the opioid levels in the bloodstream from exceeding certain parameters and also minimize addiction and side effects, enabling medical practitioners to offer pain patients and employ effective opioid-based pain management systems.
- Sector
- Healthcare
- HQ
- Akron, OH, United States
- Founded
- 2013
- Employees
- 4
- Website
- elysiumrx.com/
- Ownership
- Privately Held (backing)
Elysium Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elysium Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elysium Therapeutics in its N-PORT filings yet. We sweep new filings monthly.